Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Clinical Knowledge Summaries (CKS)
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Life sciences
More from NICE
Home
NICE guidance
In development
In development: Guidance, quality standards and advice
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter (1 applied)
Skip to results
Keyword or reference number
Keyword or reference number
Apply filter
Expected publication date
Expected publication date
From date
To date
Apply date filters
Area of interest
Area of interest
COVID-19 (5)
Type
(
1 selected
)
Type
Guidance (373)
NICE advice (1)
Quality standard (8)
Guidance programme
Guidance programme
Clinical guidelines (25)
Diagnostics guidance (6)
Health technology evaluations (14)
Highly specialised technologies guidance (5)
Interventional procedures guidance (15)
Medical technologies guidance (8)
NICE guidelines (30)
Public health guidelines (1)
Technology appraisal guidance (300)
Apply filters
Showing 211 to 220 of 373
Sort by
Title
Date
Apply sorting
Type: Guidance
Remove Type: Guidance filter
Guidance, NICE advice and quality standards in development
Title
Type
Expected publication date
Nitazoxanide for treating the common cold in people 12 years and over [ID4049]
Technology appraisal guidance
TBC
Nivolumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID6310]
Technology appraisal guidance
17 December 2025
Nivolumab for adjuvant treatment of high-risk hepatocellular carcinoma after liver resection or ablation [ID3858]
Technology appraisal guidance
17 July 2024
Nivolumab for adjuvant treatment of resected non-small-cell lung cancer [ID4053]
Technology appraisal guidance
TBC
Nivolumab with chemotherapy for untreated unresectable or metastatic urothelial cancer [ID5102]
Technology appraisal guidance
TBC
Nivolumab with ipilimumab for untreated unresectable or metastatic urothelial cancer when cisplatin is unsuitable [ID3939]
Technology appraisal guidance
TBC
Nivolumab with ipilimumab for untreated unresectable stage 3 non-small-cell lung cancer [ID6248]
Technology appraisal guidance
TBC
Nivolumab–relatlimab for adjuvant treatment of resected stage 3 or 4 melanoma in people 12 years and over [ID6475]
Technology appraisal guidance
TBC
Nogapendekin alfa inbakicept with intravesical BCG for previously treated non-muscle-invasive bladder cancer unresponsive to BCG ID6582
Technology appraisal guidance
30 September 2026
Non-invasive skin closure devices for surgical incisions (MT775)
Medical technologies guidance
TBC
Previous page
1
…
20
21
Current page
22
23
24
…
38
Page
22
of
38
Next page
Results per page
10
25
50
All
Back to top